ArticleHealth science reports2026
Predictors of Mortality in COVID-19 Patients Presenting With Gastrointestinal Bleeding: A Retrospective Cross-Sectional Study.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Coronavirus disease 2019 (COVID-19), since its outbreak, has been a potentially fatal disorder. Gastrointestinal bleeding (GIB) with a notable prevalence of 1.5%-3% has been identified as a prominent cause of death in COVID-19 patients. This study was conducted to evaluate GIB prevalence and mortality rate in COVID-19 patients and to assess the role of potential risk factors on patient outcomes. Methods: In this retrospective cross-sectional study, the records of RT-PCR confirmed COVID-19 patients who presented with overt GIB symptoms (melena, hematochezia, and hematemesis) in their course of admission or hospitalization in Isfahan Shariati Hospital, between March 2020 and 2022, were enrolled. After exclusion, data on patients' demographics, comorbid conditions, manifestations of GIB, bleeding onset, and anticoagulant administration were extracted. Subjects were divided into two groups: alive and deceased 30 days after discharge to assess the role of variables on mortality. Results: Among 7243 COVID-19 patients, 107 (1.5%) individuals experienced GIB symptoms. After excluding patients with GIB not attributable to COVID-19, 63 patients (0.86%) were included in the analysis, of whom 47.6% were reported deceased. The most common manifestations were hematemesis (42.9%) and melena (33.3%), indicating 76.2% of the upper GIB source. 61.9% of GIBs occurred during hospitalization, and the prevalence of hypertension, diabetes, and cardiovascular disease was 39.7%, 31.7%, and 19%, respectively. Endoscopic evaluation was performed in 12 patients, with gastric and duodenal ulcers being the most frequent findings (5 cases, 41.6%). Other than a significant association between the outcomes and the onset of bleeding ( Conclusion: GIB developing during hospitalization, as opposed to bleeding that occurred prior to admission, was suggested as a prognostic factor of mortality in COVID-19 patients. Considering the fatal consequences of GIB in COVID-19 patients, further studies are recommended to assess the roles of risk factors in preventing adverse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.